JP2008505983A5 - - Google Patents

Download PDF

Info

Publication number
JP2008505983A5
JP2008505983A5 JP2007527402A JP2007527402A JP2008505983A5 JP 2008505983 A5 JP2008505983 A5 JP 2008505983A5 JP 2007527402 A JP2007527402 A JP 2007527402A JP 2007527402 A JP2007527402 A JP 2007527402A JP 2008505983 A5 JP2008505983 A5 JP 2008505983A5
Authority
JP
Japan
Prior art keywords
compound
subject
composition
compound according
imaging
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2007527402A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008505983A (ja
Filing date
Publication date
Priority claimed from US10/848,741 external-priority patent/US6995260B2/en
Application filed filed Critical
Publication of JP2008505983A publication Critical patent/JP2008505983A/ja
Publication of JP2008505983A5 publication Critical patent/JP2008505983A5/ja
Pending legal-status Critical Current

Links

JP2007527402A 2004-05-20 2005-05-17 カルボラニルポルフィリン及びそれらの使用 Pending JP2008505983A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/848,741 US6995260B2 (en) 2004-05-20 2004-05-20 Carboranylporphyrins and uses thereof
PCT/US2005/017358 WO2006088476A2 (en) 2004-05-20 2005-05-17 Carboranylporphyrins and uses thereof

Publications (2)

Publication Number Publication Date
JP2008505983A JP2008505983A (ja) 2008-02-28
JP2008505983A5 true JP2008505983A5 (enExample) 2008-07-03

Family

ID=35375345

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2007527402A Pending JP2008505983A (ja) 2004-05-20 2005-05-17 カルボラニルポルフィリン及びそれらの使用

Country Status (11)

Country Link
US (1) US6995260B2 (enExample)
EP (1) EP1753468A4 (enExample)
JP (1) JP2008505983A (enExample)
KR (1) KR20070026552A (enExample)
CN (1) CN1968705A (enExample)
AU (1) AU2005327597B2 (enExample)
CA (1) CA2567468A1 (enExample)
IL (1) IL179497A0 (enExample)
NO (1) NO20065858L (enExample)
NZ (1) NZ551732A (enExample)
WO (1) WO2006088476A2 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2397067B (en) * 2002-12-23 2005-05-11 Destiny Pharma Ltd Porphin & azaporphin derivatives with at least one cationic-nitrogen-containing meso-substituent for use in photodynamic therapy & in vitro sterilisation
US20070093463A1 (en) * 2004-05-20 2007-04-26 Brookhaven Science Associates, Llc Radiation enhancement agent for X-ray radiation therapy and boron neutron-capture therapy
GB2415372A (en) 2004-06-23 2005-12-28 Destiny Pharma Ltd Non photodynamical or sonodynamical antimicrobial use of porphyrins and azaporphyrins containing at least one cationic-nitrogen-containing substituent
GB0427589D0 (en) 2004-12-16 2005-01-19 Psimei Pharmaceuticals Plc Process for the preparation of a substituted porphyrin
US8287839B2 (en) * 2006-12-04 2012-10-16 Brookhaven Science Associates, Llc Carboranylporphyrins and uses thereof
WO2008102669A1 (ja) * 2007-02-19 2008-08-28 Rei Medical Co., Ltd. 新規な糖連結クロリン誘導体及びその製造方法
US8444953B2 (en) * 2007-03-22 2013-05-21 Brookhaven Science Associates, Llc Symmetric and asymmetric halogen-containing metallocarboranylporphyrins and uses thereof
US20080279781A1 (en) * 2007-05-10 2008-11-13 Brookhaven Science Associates, Llc Glycosylated Carboranylporphyrins and Uses Thereof
JP5745415B2 (ja) * 2009-09-17 2015-07-08 国立大学法人九州大学 ポルフィリン化合物
WO2011050575A1 (en) * 2009-10-28 2011-05-05 The University Of Hong Kong Hydroxy-substituted gold(iii) porphyrin complexes as histone deacetylase inhibitors
CN102268003B (zh) * 2011-06-16 2013-10-30 扬州大学 不对称多取代卟啉金(iii)类抗癌化合物及其制备方法
GB201221125D0 (en) * 2012-11-23 2013-01-09 Morex Dev Partners Llp Pharmaceutial formulations
KR102885276B1 (ko) * 2021-07-13 2025-11-11 삼성에스디아이 주식회사 염료, 이를 포함하는 조성물, 필름, 광학 부재 및 디스플레이 장치
CN114015066B (zh) * 2021-11-12 2022-08-12 北京大学 共价有机框架材料、其制备方法和用途

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4783529A (en) * 1985-12-03 1988-11-08 Research Corporation Technologies Rapid synthesis of radiolabeled porphyrin complexes for medical application
US5162231A (en) * 1989-10-25 1992-11-10 Cole Dean A Method of using 5,10,15,20-tetrakis(carboxyphenyl)porphine for detecting cancers of the lung
US4959356A (en) * 1989-05-26 1990-09-25 The United States Of America As Represented By The United States Department Of Energy Porphyrins for boron neutron capture therapy
FR2656866B1 (fr) * 1990-01-10 1992-05-15 Cis Bio Int Derives de porphyrine et metalloporphyrines eventuellement couples a une molecule biologiquement active, et composition pharmaceutique les contenant.
US5654423A (en) * 1990-11-21 1997-08-05 Regents Of The University Of California Boronated metalloporphyrine and therapeutic methods
US5149801A (en) * 1990-11-21 1992-09-22 The Regents Of The University Of California Boronated porphyrin compounds
US5312896A (en) * 1992-10-09 1994-05-17 Sri International Metal ion porphyrin-containing poly(imide)
DE4305523A1 (de) * 1993-02-17 1994-08-18 Diagnostikforschung Inst Meso-Tetraphenylporphyrin-Komplexverbindungen, Verfahren zu ihrer Herstellung und diese enthaltende pharmazeutische Mittel
US5563132A (en) * 1994-06-21 1996-10-08 Bodaness; Richard S. Two-step cancer treatment method
US5648485A (en) * 1994-10-26 1997-07-15 University Of British Columbia β, β-dihydroxy meso-substituted chlorins, isobacteriochlorins, and bacteriochlorins
US5877165A (en) * 1995-11-02 1999-03-02 Brookhaven Science Associates Boronated porhyrins and methods for their use
US5955586A (en) * 1996-03-22 1999-09-21 Sessler; Jonathan L. Highly boronated derivatives of texaphyrins
WO1998030102A1 (en) * 1997-01-09 1998-07-16 Emory University Non-iron metalloporphyrins and methods of use
US6010805A (en) * 1998-05-26 2000-01-04 United States Of America As Represented By The Secretary Of The Air Force Ion conducting electrolyte material containing a lithium porphyrin complex
AU2001274827A1 (en) 2000-05-09 2001-11-20 The Regents Of The University Of California Porphyrin-based neutron capture agents for cancer therapy
US6566517B2 (en) * 2001-06-06 2003-05-20 Brookhaven Science Associates, Llc Metalloporphyrins and their uses as imageable tumor-targeting agents for radiation therapy
US7087214B2 (en) * 2002-02-01 2006-08-08 Zentaris Gmbh Water-soluble porphyrin platinum compounds with high tumor selectivity and their use for the treatment of benign and malignant tumor diseases
GB0222945D0 (en) * 2002-10-03 2002-11-13 Psimei Pharmaceuticals Plc Therapeutic compositions

Similar Documents

Publication Publication Date Title
JP2010511704A5 (enExample)
RU2009121323A (ru) Карборанилпорферины и их применение
JP2008505983A5 (enExample)
Aihara et al. First clinical case of boron neutron capture therapy for head and neck malignancies using 18F‐BPA PET
Miyatake et al. Boron neutron capture therapy for malignant brain tumors
Masunaga et al. The dependency of compound biological effectiveness factors on the type and the concentration of administered neutron capture agents in boron neutron capture therapy
CN1279907C (zh) 新的金属卟啉化合物及其在放射疗法中用作放射增敏剂的用途
Zou et al. 68Ga-labeled magnetic-NIR persistent luminescent hybrid mesoporous nanoparticles for multimodal imaging-guided chemotherapy and photodynamic therapy
Fukuda et al. Boron neutron capture therapy (BNCT) for malignant melanoma with special reference to absorbed doses to the normal skin and tumor
Yuan et al. Boron neutron capture therapy of cancer: Critical issues and future prospects
JP2008504365A5 (enExample)
Garabalino et al. Boron neutron capture therapy (BNCT) for the treatment of liver metastases: biodistribution studies of boron compounds in an experimental model
Bianfei et al. Application of Cherenkov radiation in tumor imaging and treatment
Wei et al. X-ray/γ-ray/Ultrasound-Activated Persistent Luminescence Phosphors for Deep Tissue Bioimaging and Therapy
JP6170147B2 (ja) 癌治療
Fazaeli et al. 68Ga CdTe/CdS fluorescent quantum dots for detection of tumors: investigation on the effect of nanoparticle size on stability and in vivo pharmacokinetics
Golshani et al. Gadolinium neutron capture therapy: Calculation of 157Gd kerma factor and a dosimetry study using MCNP Monte Carlo code
CA2572287A1 (en) Carboranylporphyrins and uses thereof
Fujibayashi et al. Imaging and therapy against hypoxic tumors with 64Cu-ATSM
Brandão et al. Intracavitary moderator balloon combined with 252Cf brachytherapy and boron neutron capture therapy, improving dosimetry in brain tumour and infiltrations
JP2014177421A (ja) 陽子線治療用増感剤、及びそれを用いた陽子線治療法
McGovern et al. Case report of a dog treated with radioactive iodine (I131) and stereotactic body radiation therapy (SBRT) for metastatic ectopic thyroid carcinoma
Masunaga et al. Effect of a change in reactor power on response of murine solid tumors in vivo, referring to impact on quiescent tumor cell population
Ajlouni Radiotherapy by Neutron-Irradiated Nanoparticles
Young AgTPPS (4) enhanced brachytherapy as a treatment for inoperable brain tumors